<scp>TAK</scp>1 Inhibition in the <scp>DFG</scp>‐Out Conformation
Iain Kilty(Pfizer (United States)), Lyn H. Jones(Harvard University), Christopher Phillips(AstraZeneca (Brazil)), Willem P. van Hoorn(Pfizer (United Kingdom)), Martin P. Green(Pfizer (United Kingdom)), Samantha Jane Hughes(University of Trás-os-Montes and Alto Douro), Christopher A. Hewson(Pfizer (United Kingdom)), Thomas Ryckmans(Pfizer (United Kingdom)), Peter G. Dodd(Pfizer (United Kingdom)), Andrew Bell(Pfizer (United Kingdom)), David G. Brown(Pfizer (United Kingdom)), R T Smith(Pfizer (United Kingdom)), Philip Cohen(MRC Protein Phosphorylation and Ubiquitylation Unit)
Cited by 18
Related Papers
GSK3 takes centre stage more than 20 years after its discovery
|Biochemical Journal|2001|1.3k
Kinase drug discovery 20 years after imatinib: progress and future directions
|Nature Reviews Drug Discovery|2021|1k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Global mapping of pharmacological space
|Nature Biotechnology|2006|820
Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B
|Journal of Biological Chemistry|1999|717